When was Braeburn founded?

Braeburn was founded in 2012 and raised its 1st funding round 6 years after it was founded.

Where is Braeburn located?

Braeburn is headquartered in Philadelphia, United States.

How many employees does Braeburn have?

As of Sep 30, 2026, the latest employee count at Braeburn is 334.

Is Braeburn a funded company?

Braeburn is a funded company, having raised a total of $110M across 2 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Jan 08, 2018.

How much is Braeburn worth?

The latest valuation of Braeburn is $***** as of Jan 01, 2018.

When was the latest funding round of Braeburn?

Braeburn's latest funding was a $***** Conventional Debt round on Jan 10, 2018, with participation from 7 investors.

Where does Braeburn rank among its competitors?

Braeburn ranks 46th amongst 2077 active competitors, of which 462 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of Braeburn?

Braeburn's top competitors include Antheia, Transcenta and Akeso. Among them, One Biosciences secured the most recent funding round in September, 2026.

Braeburn - 2026 Company Profile, Funding & Competitors

Company Details

Braeburn is focused on developing long-acting implantable and injectable therapies for opioid addiction & chronic pain. The company's lead product, Probufine (buprenorphine implant) is approved by FDA for opioid dependence. Another product, CAM2038 is in NDA refilling process for opioid dependence & in phase 3 for pain management. CAM2038 is delivered SC route & a long-acting formulation developed using proprietary system known as FluidCrystal.

Website: braeburnrx.com
Social
Email ID: *****@braeburnrx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Philadelphia, United States

Stage

Series D

Total Funding

$110M in 2 rounds

Latest Funding Round

Conventional Debt, Jan 10, 2018, $*****

Post Money Valuation

$***** as on Jan 01, 2018

Investors

RA Capital Management & 6 more

Ranked

46^th among 2077 active competitors

Employee Count

334 as on Sep 30, 2026

Similar Companies

Antheia & 2791 more

View Braeburn's full profile

Braeburn has raised a total funding of $110M over 2 rounds. Its first funding round was on Jan 08, 2018. Its latest funding round was a Conventional Debt round on Jan 10, 2018 for $*****. 7 investors participated in its latest round. Braeburn has 7 institutional investors.

Here is the list of recent funding rounds of Braeburn:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2018	8190382	Conventional Debt	6846221	7139411	9660761	5210915
Jan 08, 2018	2046268	Series D	2416407	7784367	6559021	6378230

Access funding benchmarks and valuations. Sign up today!

View details of Braeburn's funding rounds and investors

Braeburn's employee count trend

Braeburn has 334 employees as of Sep 26. Here is Braeburn's employee count trend over the years:

Uncover Braeburn's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Braeburn include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Braeburn, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Indivior 2014, Richmond Hill (United States), Public	Therapeutics for addiction treatment	-	Digital Pharma Lab, Athyrium Capital Management ... & 1 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
9th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
46th	Braeburn 2012, Philadelphia (United States), Series D	Developing long acting formulation for opioid addiction	$110M	RA Capital Management, New Leaf Venture Partners ... & 5 others	56/100